How does sapropterin dosage account for patient's comorbidities?

Short answer: sapropterin dosing is not generally adjusted for most comorbidities. Dosing is guided mainly by weight and the patient’s biochemical response (serum phenylalanine, Phe) rather than by comorbidity type.

Key points:
- Starting dose for phenylketonuria (PKU) is 10 mg/kg/day, given once daily (or divided).
- If no adequate Phe reduction after 1–2 weeks, titrate up to 20 mg/kg/day. Maximum: 20 mg/kg/day or 1,000 mg/day, whichever is lower.
- There are no formal dose adjustments recommended specifically for hepatic or renal impairment in the label. In other words, comorbidities do not have a defined dosing algorithm separate from Phe monitoring.
- The main monitoring parameter is serum phenylalanine concentration (and tolerability). Watch for hypophenylalaninemia and adverse effects.
- If a patient has other BH4-responsive conditions or DHPR deficiency, dosing/or therapy may differ and should be guided by a specialist.

Practical approach:
- Start at 10 mg/kg/day and recheck Phe after 1–2 weeks.
- If Phe remains high or dietary Phe tolerance is not improved, increase to 20 mg/kg/day and re-evaluate.
- Throughout, monitor Phe levels and adjust dose accordingly rather than adjusting for a comorbidity alone. If you have a specific comorbidity in mind (e.g., severe liver disease), discuss with a clinician or metabolic specialist for any special considerations.